Skip to main content
. Author manuscript; available in PMC: 2015 Oct 26.
Published in final edited form as: Lung. 2012 Jul 19;190(5):523–527. doi: 10.1007/s00408-012-9410-z

Table 2.

Change in secondary markers of lung function over 12 months of losartan therapy

N (%) FEV1 DLCO 6MWT distance
Stable 8 (47.06) 10 (58.82) 6 (35.29)
Improved 2 (11.76) 2 (11.76) 5 (29.41)
Deteriorated 7 (41.18) 5 (29.42) 6 (−1.38)

FEV1 forced expiratory volume 1 second, DLCO diffusing capacity for carbon monoxide